RAGE Antibodies Patent Granted SUNY Apr 14

USPTO granted Patent US12600778B2 to The Research Foundation for The State University of New York on April 14, 2026. The patent covers antibodies specific for the heparan sulfate binding site of Receptor for Advanced Glycation Endproducts (RAGE), along with methods for treating conditions in which RAGE is involved through antibody administration. The patent application was filed November 2, 2020, under application number 17772853.

For biotech and pharmaceutical companies, this patent establishes intellectual property protection for RAGE-targeted antibody therapeutics. The 4-claim patent provides the assignee exclusive rights in the US for approximately 20 years from filing. Research institutions and companies developing RAGE-related therapies should review this patent to assess potential freedom-to-operate implications or licensing opportunities.